Patents Examined by Padmaja S Rao
-
Patent number: 12030861Abstract: An L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and forms thereof are provided. Also provided are pharmaceutical or veterinary compositions comprising this L-lysine salt and their use for treating a number of diseases.Type: GrantFiled: July 13, 2023Date of Patent: July 9, 2024Assignee: ENYO PHARMAInventors: Raphaël Darteil, Jacky Vonderscher, Diane Sampson, Nicolas Philippon, Joël Vacus, Julien Leroudier, Sandra Werner, Françoise Richard-Tiberghien
-
Patent number: 12018023Abstract: The present invention relates to certain substituted heterocondensed pyridone analogues of formula (I) which modulate the activity of Isocitrate Dehydrogenase (IDH). The compounds of this invention are therefore useful in treating diseases caused by mutated IDH1 and/or mutated IDH2 enzyme and/or IDH1 wild type enzyme, in particular cancer, cell proliferative disorders and immune-related disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.Type: GrantFiled: May 16, 2019Date of Patent: June 25, 2024Assignee: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Elena Casale, Francesco Casuscelli, Teresa Disingrini, Paola Magnaghi, Beatrice Malgesini, Ilaria Motto, Stefano Nuvoloni
-
Patent number: 12016852Abstract: Compounds of formula (I) wherein A, W, R3b, Z and p have the meaning according to the claims, can be employed, inter alia, for the treatment of taupathies and Alzheimer's disease.Type: GrantFiled: August 22, 2019Date of Patent: June 25, 2024Assignee: Asceneuron SAInventors: Anna Quattropani, Grant Wishart, Santosh S. Kulkarni, Paul Rakesh
-
Patent number: 11998539Abstract: The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 30, 2022Date of Patent: June 4, 2024Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT, DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Norbert Schmees, Lars Wortmann, Dennis Kirchhoff, Thi Thanh Uyen Nguyen, Nicolas Werbeck, Ulf Bömer, Kirstin Petersen, Christina Kober, Christian Lechner, Dirk Kosemund, Rienk Offringa, Mareike Grees, Benjamin Bader
-
Patent number: 11987586Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: October 30, 2023Date of Patent: May 21, 2024Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasushi Hattori, Marilena Pira, Yoshiteru Ito, Kohei Takeuchi, Eiji Kimura, Norihito Tokunaga, Shuhei Ikeda, Martin Alexander Pawliczek, Noriyuki Tezuka, Yasutaka Hoashi, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike
-
Patent number: 11986460Abstract: The present invention relates to a solid pharmaceutical preparation comprising ?-lipoic acid, dicalcium phosphate and a binder. The solid pharmaceutical preparation has an improved stability and thereby improved bioavailability.Type: GrantFiled: November 26, 2019Date of Patent: May 21, 2024Assignee: The Procter & Gamble CompanyInventors: Satishkumar Jain, Parminder Singh Sidhu, Paul Robinson, Madhura Rege, Sundareswarakumar Chellaswamy
-
Patent number: 11981620Abstract: A new synthetic route to 4,4?-diiodoazobenzene compound using homooxidative cross-coupling of an aryl diazonium salt using a Cu-catalyzed Sandmeyer-style reaction.Type: GrantFiled: November 28, 2023Date of Patent: May 14, 2024Assignee: KING FAISAL UNIVERSITYInventor: Obadah Subhi Abdel-Rahman
-
Patent number: 11976074Abstract: The present invention provides salts and crystalline forms of Linsitinib (OSI-906; cis-3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl-cyclobutanol). These forms of Linsitinib provide increased solubility and improved pharmacokinetic profiles for orally administered pharmaceutical formulations. Accordingly, the invention enables improved methods for treating human insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) mediated conditions.Type: GrantFiled: June 26, 2023Date of Patent: May 7, 2024Assignee: SLING THERAPEUTICS, INC.Inventors: Ronald Dadino, Ryan Zeidan
-
Patent number: 11964963Abstract: This invention relates to novel salts and crystal forms of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol, simply abbreviated as Compound A, which is a selective CB2 receptor agonist. The present invention provides a salt of Compound A, a crystal form thereof, a method for preparing the said salt and a pharmaceutical composition thereof and its use. The salts of Compound A of the present invention show good pharmaceutical formulation properties such as high aqueous solubility, good crystallinity, high melting point, good chemical and physical stability, or non-deliquescent.Type: GrantFiled: November 11, 2021Date of Patent: April 23, 2024Assignee: AskAt Inc.Inventors: Yukari Inami, Yoshiyuki Okumura, Tracy Walker
-
Patent number: 11964954Abstract: A compound N?-[(2-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide, its synthesis, and its use as an anticancer and/or antimicrobial agent.Type: GrantFiled: August 29, 2023Date of Patent: April 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Amer A. Amer, Doaa Hassan Ahmed Ali, Esam Ajlan Talag Alqurashi, Antar Ahmed Abdelhamid Ahmed
-
Patent number: 11957728Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.Type: GrantFiled: December 16, 2021Date of Patent: April 16, 2024Assignee: Sami-Sabinsa Group LimitedInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Lakshmi Mundkur
-
Patent number: 11945803Abstract: RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.Type: GrantFiled: August 6, 2019Date of Patent: April 2, 2024Assignee: Tosk, Inc.Inventors: Annie L. Lennek, Stephen D. Yanofsky, Brian D. Frenzel, Solomon B. Ungashe, William A. Garland, Philip Liaw
-
Patent number: 11931354Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.Type: GrantFiled: December 6, 2019Date of Patent: March 19, 2024Assignee: Lixte Biotechnology, Inc.Inventors: John S. Kovach, Mickey L. Wells
-
Patent number: 11918582Abstract: Disclosed herein are pyrazole pyrimidine compounds that modulate and/or inhibit hematopoietic progenitor kinase 1, as well as methods of making such compounds and therapeutic methods of using same.Type: GrantFiled: March 14, 2022Date of Patent: March 5, 2024Assignee: RAPT Therapeutics, Inc.Inventors: Cyril Bucher, Adrian Dukes, Blanca Gomez, Hannah Haley, Dennis Hu, Jeffrey J. Jackson, Michelle Yoo Min Ko, Paul Leger, Anqi Ma, Andrew A. Ng, Daniel Poon, Omar Robles, Anton Shakhmin, Grant Shibuya, Parcharee Tivitmahaisoon, Vi-Anh Vu, David J. Wustrow, Mikhail Zibinsky
-
Patent number: 11891401Abstract: The application relates to N-(4-fluoro-3-(6-(3-methylpyridin-2-yl)-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl)-2,4-dimethyloxazole-5-carboxamide (Compound I) fumaric acid co-crystals and X-ray amorphous complexes of Compound (I) and fumaric acid. The application also provides methods of making the same; pharmaceutical compositions comprising them; and their use in treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a kinetoplastid parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.Type: GrantFiled: October 8, 2019Date of Patent: February 6, 2024Assignee: NOVARTIS AGInventors: Yudong Cao, Siyi Jiang, Hongyong Kim, Andreas Kordikowski, Irene Xia, Bo Yu, Jing Zhang, Yi Zhao
-
Patent number: 11883393Abstract: This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.Type: GrantFiled: December 18, 2020Date of Patent: January 30, 2024Assignee: Arvinas Operations, Inc.Inventors: Lawrence B. Snyder, Hanqing Dong
-
Patent number: 11883387Abstract: The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.Type: GrantFiled: July 3, 2019Date of Patent: January 30, 2024Assignee: Helmholtz-Zentrum Für Infektionsforschung GmbHInventors: Ahmed S. A. Ahmed, Martin Empting, Mostafa Hamed, Rolf W. Hartmann, Jörg Haupenthal, Thomas Hesterkamp, Ahmed A. M. Kamal, Christine K. Maurer, Teresa Röhrig, Christian Schütz, Samir Yahiaoui, Michael Zender
-
Patent number: 11878965Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.Type: GrantFiled: December 21, 2021Date of Patent: January 23, 2024Assignee: Gilead Sciences, Inc.Inventors: Daniel H. Byun, Zhenhong R. Cai, Eda Y. Canales, Laurent P. Debien, Timothy R. Hansen, Richard Huang, Petr Jansa, Rick A. Lee, Jennifer A. Loyer-Drew, Ryan McFadden, Michael L. Mitchell, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Joshua J. Van Veldhuizen, Lianhong Xu
-
Patent number: 11873279Abstract: The present disclosure relates to the discovery that certain ocular diseases may be treated using Edonentan crystalline forms. Specific Edonentan crystalline form can be used alone or in combination with an intra-ocular pressure (TOP) reducing agent, a neuroprotective agent, or an anti-VEGF agent. Using Edonentan crystalline forms, alone or in combination with an additional agent, provides increased perfusion to the retina or reduced IOP in certain ocular diseases and reduces damage to retinal cells.Type: GrantFiled: August 2, 2022Date of Patent: January 16, 2024Assignee: Perfuse Therapeutics, Inc.Inventors: Sevgi Gurkan, David Floyd, Zhongli Ding
-
Patent number: 11866416Abstract: The present invention is related to the inhibition of the formation of Streptococci biofilms through the inhibition of glucosyl transferase (Gtf). Compounds, compositions and methods for inhibiting Streptococcus biofilm formation, as well as for preventing, inhibiting and/or treating the formation of dental caries, and methods of identifying compounds that prevent, inhibit and/or treat the formation of dental caries are provided.Type: GrantFiled: April 3, 2019Date of Patent: January 9, 2024Assignee: UAB Research FoundationInventors: Sadanandan E. Velu, Hui Wu, Qiong Zhang, Bhavitavya Nijampatnam